Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
Status:
Terminated
Trial end date:
2019-10-18
Target enrollment:
Participant gender:
Summary
The primary objective of the phase Ib of the study is to determine the recommended phase 2
dose (RP2D) for entospletinib (ENTO) in patients treated with R-CHOP.
The primary objective of the phase II is to determine the complete metabolic response (CMR)
rate by the Lugano classification 2014 (Deauville scale 1-3) at the end of treatment.